Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
NYU Langone Health
Incyte Corporation
Bristol-Myers Squibb
Sarcoma Oncology Research Center, LLC
University of California, San Francisco
Eisai Inc.
Kyowa Kirin Co., Ltd.
Novo Nordisk A/S
University of California, Davis
M.D. Anderson Cancer Center
Abramson Cancer Center at Penn Medicine
Incyte Corporation
Northwestern University
Transgene
Celgene
Bristol-Myers Squibb